We further analysed the distribution of SMGs in TCGA‐CRC based on various clinical features, including age, gender, TNM stage, microsatellite instability (MSI) status, molecular subtype and TP53/KRAS/BRAF mutation status (Figures 2B and S7A–K). This evidence concerns the gene KRAS and colorectal carcinoma.